February 21, 2024Journal of Clinical Oncology241 citationsOpen Access
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Key points are not available for this paper at this time.
Abstract
Jco
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial | Synapse